ClinicalTrials.gg
CompletedNCT00674115Updated Mar 11, 2015Results posted

A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (CL2007-17 )(P07813)(COMPLETED)

A Phase 3 interventional study of Omeprazole/sodium bicarbonate and omeprazole magnesium in Gastric Acid and Human Experimentation, sponsored by Bayer. Completed. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-03-11.

Sponsored by Bayer · Phase 3 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Open-label randomized crossover design studies. 60 participants will be evaluated on Day 1 to compare effects on stomach acid; 30 participants will continue treatment for 7 days and will have repeat evaluations at Day 7. The other 30 participants will receive a single administration of sodium bicarbonate.

Read the detailed description

Enrolled participants were divided into 2 groups, with 30 participants in each group.

Group 1: This group was randomized into a 2-way crossover design with an added third period. These participants received single administrations (day 1 dosing only) of Zegerid Powder for Oral Suspension, and Prilosec OTC (both at a 20 mg omeprazole dose), in a 2-way randomized order, with a minimum of a 2-week washout period between treatment legs. Following completion of the 2-way crossover study, and a subsequent washout period (minimum of 2 weeks), all participants then received a single administration of sodium bicarbonate (at same dose as contained in Zegerid Powder for Oral Suspension) in Period 3. This group underwent a 24-hour intragastric pH study on each of the 3 dosing occasions.

Group 2: This group was randomized into a 2-way crossover design in which they received 7 days administration of Zegerid Powder for Oral Suspension and Prilosec OTC tablets, respectively. As with the prior group, there was a minimum of a 2-week washout period between treatment legs. Participants assigned to this treatment group also underwent 24-hour intragastric pH recordings on the days on which they received their 1st and last (7th) dose of the two treatment drugs.

In addition to the above detailed procedures, all participants (both groups) underwent a 24-hour baseline intragastric pH study prior to starting their randomized treatments. This study design enabled all 60 participants to be evaluated for effects of the first dose of Prilosec OTC and Zegerid Powder for Oral Suspension on change in intragastric pH during the subsequent 24-hour period following the first dose.

02

Conditions studied

  • Gastric Acid
  • Human Experimentation
03

In context

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Normal subjects who are 18-65 years of age.
  • Non- females or those using .

Exclusion criteria

Exclusion Criteria:

  • History of , allergy or intolerance to omeprazole or other proton pump inhibitors
  • History of significant gastrointestinal disease
  • Any significant medical illness
  • Gastrointestinal disorder or surgery leading to impaired drug absorption
  • Currently using gastrointestinal medications
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Single Dose Zegerid for 1 or 7 days

    Omeprazole 20 mg/Sodium Bicarbonate 1680 mg Powder for Oral Suspension

    Drug: Omeprazole/sodium bicarbonate

  • Active comparator
    Single Dose Prilosec 1 or 7 days

    Omeprazole magnesium 20 mg over-the-counter (OTC) Tablet

    Drug: omeprazole magnesium

  • Active comparator
    Sodium Bicarbonate

    Sodium Bicarbonate 1680 mg Oral Suspension

    Drug: sodium bicarbonate

Interventions

  • DrugOmeprazole/sodium bicarbonate

    Drug pages: Omeprazole · Sodium Bicarbonate

    Omeprazole/sodium bicarbonate. Single dose per day for either 1 or 7 days.

    Also known as: Zegerid

  • Omeprazole 20 mg tablet. Single dose per day for either 1 or 7 days.

    Also known as: Prilosec OTC Tablet

  • Sodium bicarbonate. Single dose.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Median 24-hour Intragastric pH on the 7th Day of Drug Administration

    The change from Baseline in median pH was calculated as: median pH on Day 7 minus median pH at Baseline. PH measures how acidic or basic a substance is. The pH scale ranges from 0 to 14. A pH of 7 is neutral. A pH less than 7 is acidic. A pH greater than 7 is basic.

    Time frame: Baseline and 7 days

07

Results

Posted Apr 30, 2010

Participant flow

First Intervention
Participant flow — First Intervention
MilestoneZegerid, Prilosec, Sodium BicarbonatePrilosec, Zegerid, Sodium BicarbonateZegerid, PrilosecPrilosec, Zegerid
Started14161416
Completed14161416
Not completed0000
Washout Period of 2 Weeks
Participant flow — Washout Period of 2 Weeks
MilestoneZegerid, Prilosec, Sodium BicarbonatePrilosec, Zegerid, Sodium BicarbonateZegerid, PrilosecPrilosec, Zegerid
Started14161416
Completed14161416
Not completed0000
Second Intervention
Participant flow — Second Intervention
MilestoneZegerid, Prilosec, Sodium BicarbonatePrilosec, Zegerid, Sodium BicarbonateZegerid, PrilosecPrilosec, Zegerid
Started14161416
Completed14161416
Not completed0000
Washout Period of 2 Weeks
Participant flow — Washout Period of 2 Weeks
MilestoneZegerid, Prilosec, Sodium BicarbonatePrilosec, Zegerid, Sodium BicarbonateZegerid, PrilosecPrilosec, Zegerid
Started141600
Completed141600
Not completed0000
Third Intervention
Participant flow — Third Intervention
MilestoneZegerid, Prilosec, Sodium BicarbonatePrilosec, Zegerid, Sodium BicarbonateZegerid, PrilosecPrilosec, Zegerid
Started141600
Completed141600
Not completed0000

Outcome measures

PrimaryChange From Baseline in Median 24-hour Intragastric pH on the 7th Day of Drug Administration

The change from Baseline in median pH was calculated as: median pH on Day 7 minus median pH at Baseline. PH measures how acidic or basic a substance is. The pH scale ranges from 0 to 14. A pH of 7 is neutral. A pH less than 7 is acidic. A pH greater than 7 is basic.

Time frame:
Baseline and 7 days
Reported as:
Median · pH scale
Change From Baseline in Median 24-hour Intragastric pH on the 7th Day of Drug Administration
pH scaleZegeridPrilosec
Day 7 Score3.250 ± 1.3004.160 ± 1.260
Change from Baseline in PH2.180 ± 1.3202.900 ± 1.244

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zegerid (7-Day Dosing)—0/30 (0%)2/30 (6.7%)
Prilosec (7-Day Dosing)—0/30 (0%)2/30 (6.7%)
Sodium Bicarbonate (1-Day Dosing)—0/30 (0%)0/30 (0%)
Zegerid (1-Day Dosing)—0/30 (0%)0/30 (0%)
Prilosec (1-Day Dosing)—0/30 (0%)0/30 (0%)
Most frequent other events
Most frequent other events
EventZegerid (7-Day Dosing)Prilosec (7-Day Dosing)Sodium Bicarbonate (1-Day Dosing)Zegerid (1-Day Dosing)Prilosec (1-Day Dosing)
DiarrheaGastrointestinal disorders2/302/300/300/300/30

Baseline characteristics

Age, Continuous
Age, Continuous(years)Entire Study Population
Mean25.3 ± 4.37
Sex: Female, Male
Sex: Female, Male(Participants)Entire Study Population
Female22
Male38
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2010, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2008
First posted
May 7, 2008
Start
Apr 2008
Primary completionActual
Jun 2008
CompletionActual
Jun 2008
Results first posted
Apr 30, 2010
Last update
Mar 11, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00674115
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
May 7, 2008
Start date
Apr 2008
Primary completion
Jun 2008
Completion
Jun 2008
Results posted
Apr 30, 2010
Last update
Mar 11, 2015

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Omeprazole · Sodium Bicarbonate

Start the discussion